Efficacy of Unani formulation in stomach reflux disorder
- Conditions
- Health Condition 1: K219- Gastro-esophageal reflux disease without esophagitis
- Registration Number
- CTRI/2022/03/041538
- Lead Sponsor
- Rajiv Gandhi University of Health Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Subjects of uncomplicated symptomatic GERD in accordance with the Montreal definition
GerdQ score of 8 or more
Patients with symptomatic GERD with heartburn >=2 times weekly for the past 2 months
BMI < 40 kg/m2
Patients between 18 to 65 years of age of any gender
Patients willing to take part in the study
Patients with alarming symptoms like unintentional weight loss, recurrent vomiting, dysphasia, odynophagia, gastrointestinal bleeding, malena and anemia.
History of any serious gastrointestinal disease including peptic ulcer malignancy and dysmotility
Previous endoscopic diagnosis of erosive gastroesophagitis or Barretts esophagus.
Prior gastric or esophageal surgery for the treatment of GERD
Pregnant and lactating females
Patients of Systemic illness like cancer, epilepsy, kidney, cardiac and pulmonary diseases.
Patients who had used more than 3 doses of histamine-2 receptor antagonists or PPI within the week before randomization
Patients who had participated in an investigational drug or investigational device study within 30 days prior to the baseline visit
Patients who fail to give consent for the trial and follow up
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method